1. Nayler WG. Amlodipine. Berlin: Springer-Verlag 1993.
2. Donelly R, Meredith PA, Miller SHK et al. Pharmacodynamic modeling of the antihypertensive response to amlodipine. Clin Pharmacol Ther 1993; 54: 303–10.
3. Bainbridge AD, Herlihy PA, Meredith PA, Elliott HL. A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic in incites. Eur J Clin Pharmacol 1993; 45: 425–30.
4. Hernandez RH, Armas-Hernaґndez MJ, Zafar HI, Armas-Padilla MC. Calcium antagonists and atherosclerosis protection in hypertension. Am J Therap 2003; 10: 409–14.
5. Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 1991; 34: 869–77.
6. Phillips JE, Mason RP. Inhibition of oxidized LDL aggregation with a charged calcium antagonist amlodipine: role of electrostatic interactions. Atherosclerosis 2003; 168: 239–44.
7. Mason RP, Walter MF, Trumbore MW et al. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol 1999; 31: 275–81.
8. Zhang X-P, Xu X, Nasjletti A, Hintze TH. Amlodipine enhances NO production induced by an ACE inhibitor through a kinin-mediated mechanism in canine coronary microvessels. J Cardiovasc Pharmacol 2000; 35: 195–202.
9. Xu B, X-h L, Lin G et al. Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide and kinin-dependent mechanism. Br J Pharmacol 2002; 36: 375–82.
10. Goldmann S, Stoltefuss J, Born L. Determination of the absolute configuration of the active amlodipine enantiomer as (–)-S: a correction. J Med Chem 1992; 35: 3341–4.
11. Zhang X-P, Loke KE, Mital S et al. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R-enantiomer of amlodipine. J Cardiovasc Pharmacol 2002; 39: 208–14.
12. Mital S, Magneson A, Loke KE et al. Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts. J Cardiovasc Pharmacol 2000; 36: 248–54.
13. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists. Arterioscler Thromb Vasc Biol 2003; 23: 2155–63.
14. Stepien O, Gogusev J, Zhu D-L et al. Amlodipine inhibition of serum-, thrombin-, or fibroblast growth factor-induced vascular smooth-muscle cell proliferation. J Cardiovasc Pharmacol 1998; 31: 786–93.
15. Roth M, Eickelberg O, Köhler E et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci 1996; 93: 5478–82.
16. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000; 102: 1503–10.
17. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–26.
18. Jorgensen B, Simonsen S, Endresen K et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES). J Am Coll Cardiol 2002; 35: 592–9.
19. Eisenberg MJ, Brox A, Bestawros AN. Calcium Channel Blockers: An Update/Am J Med 2004; 116: 35–43.
20. ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blockers vs diuretic. JAMA 2002; 295: 750–64.
21.Rahman M, Pressel S, Davis BR et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 936–46.
22. Jamerson K, Weber MA, Bakris GL et al for the ACCOMPLISH trial investigators. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. N Engl J Med 2008; 359: 2417–28.
23. Dahlоf B, Sever PS, Poulter NR et al. for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
24. Sever PS, Dahlöf B, Poulter N et al for the ASCOT Investigators. Lancet 2003; 361: 1149–58.
25. Williams B, Lacy PS, Thom SM et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Coundit Artery Function Evaluation (CAFÉ) study. Circulation 2006; 113: 1213–25.
26. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003; 7: 1–94.
27. Angeli F, Verdecchia P, Reboldi GP et al. Calcium Channel Blockade to Prevent Stroke in Hypertension. Am J Hypertens 2004; 17: 817–22.

М.В.Леонова

ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова, Москва